Dashboard
Manage Tickers

BMYBRISTOL MYERS SQUIBB CO

NYSE bms.com


$ 41.48 $ 0.64 (1.57 %)    

Friday, 07-Jun-2024 11:24:40 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 463.33 $ 1.78 (0.39 %)
DIA $ 389.87 $ 1.86 (0.48 %)
SPY $ 534.81 $ 1.49 (0.28 %)
TLT $ 91.78 $ 0.16 (0.17 %)
GLD $ 213.87 $ -0.42 (-0.2 %)
$ 40.88
$ 40.84
$ 0.00 x 0
$ 41.49 x 170
$ 40.84 - $ 41.55
$ 39.91 - $ 63.65
10,282,791
na
82.87B
$ 0.53
nm
TBD
na
na ($ 0.06)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 04-25-2024 03-31-2024 10-Q
2 02-13-2024 12-31-2023 10-K
3 10-26-2023 09-30-2023 10-Q
4 07-27-2023 06-30-2023 10-Q
5 04-27-2023 03-31-2023 10-Q
6 02-14-2023 12-31-2022 10-K
7 10-26-2022 09-30-2022 10-Q
8 07-27-2022 06-30-2022 10-Q
9 04-29-2022 03-31-2022 10-Q
10 02-09-2022 12-31-2021 10-K
11 10-27-2021 09-30-2021 10-Q
12 07-28-2021 06-30-2021 10-Q
13 04-29-2021 03-31-2021 10-Q
14 02-10-2021 12-31-2020 10-K
15 11-05-2020 09-30-2020 10-Q
16 08-06-2020 06-30-2020 10-Q
17 05-07-2020 03-31-2020 10-Q
18 02-24-2020 12-31-2019 10-K
19 10-31-2019 09-30-2019 10-Q
20 07-25-2019 06-30-2019 10-Q
21 04-25-2019 03-31-2019 10-Q
22 02-25-2019 12-31-2018 10-K
23 10-25-2018 09-30-2018 10-Q
24 07-26-2018 06-30-2018 10-Q
25 04-26-2018 03-31-2018 10-Q
26 02-13-2018 12-31-2017 10-K
27 10-26-2017 09-30-2017 10-Q
28 07-27-2017 06-30-2017 10-Q
29 04-27-2017 03-31-2017 10-Q
30 02-21-2017 12-31-2016 10-K
31 10-27-2016 09-30-2016 10-Q
32 07-28-2016 06-30-2016 10-Q
33 04-28-2016 03-31-2016 10-Q
34 02-12-2016 12-31-2015 10-K
35 10-27-2015 09-30-2015 10-Q
36 07-23-2015 06-30-2015 10-Q
37 04-28-2015 03-31-2015 10-Q
38 02-13-2015 12-31-2014 10-K
39 10-24-2014 09-30-2014 10-Q
40 07-24-2014 06-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

fda-approves-gerons-first-commercial-drug-competes-with-bristol-myers-squibbs-blood-cancer-drug
FDA Approves Geron's First Commercial Drug...
06/07/2024 13:49:10

FDA approves Geron's Rytelo (imetelstat) for adults with low-to intermediate-1 risk myelodysplastic syndromes and transfusi...

why-is-mid-cap-cancer-focused-replimune-stock-trading-higher-on-thursday
Why Is Mid-Cap Cancer-Focused Replimune St...
06/06/2024 16:16:20

Replimune reported that the IGNYTE clinical trial of RP1 plus nivolumab in anti-PD1 failed melanoma showed a 33.6% response rat...

Core News & Articles
I-Mab Enters Clinical Collaboration With B...
06/05/2024 11:02:19

The collaboration will evaluate the combination of givastomig, an investigational Claudin 18.2 x 4-1BB bispecific antibody join...

bristol-myers-squibb-announces-phase-3-results-of-opdivoyervoy-combo-in-liver-cancer-patients
Bristol Myers Squibb Announces Phase 3 Res...
06/04/2024 15:35:18

Opdivo plus Yervoy combo shows significant survival benefits and higher response rates vs. lenvatinib/sorafenib in HCC.

bristol-myers-squibb-announces-presentation-of-phase-3-checkmate--9dw-trial-data-showing-opdivo-plus-yervoy-improved-overall-survival-compared-to-lenvatinib-or-sorafenib-in-advanced-hepatocellular-carcinoma
Bristol Myers Squibb Announces Presentatio...
06/04/2024 12:14:11

why-us-drug-giant-bristol-myers-squibb-stock-trading-up-on-monday
Why US Drug Giant Bristol Myers Squibb Sto...
06/03/2024 16:51:37

Bristol Myers Squibb's KRYSTAL-12 study reveals Krazati's significant benefits over chemotherapy for KRASG12C-mutated N...

bristol-myers-squibb-announces-data-from-three-studies-on-breyanzi-for-large-b-cell-lymphoma-mantle-cell-lymphoma-and-follicular-lymphoma
Bristol Myers Squibb Announces Data From T...
06/03/2024 14:13:54

bristol-myers-squibb-reveals-opdivo-results-for-lung-cancer-at-asco-2024
Bristol Myers Squibb Reveals Opdivo Result...
06/03/2024 12:03:30

Bristol Myers Squibb (NYSE:BMY) today announced results from three updated analyses from the CheckMate -77T, CheckMate -816, an...

reported-saturday-bristol-myers-squibbs-krazati-study-showed-noteworthy-progression-free-survival-in-phase-3-study-of-krasg12c-mutated-advanced-nsclc
Reported Saturday, Bristol Myers Squibb's ...
06/03/2024 08:11:16

First presentation of data from Phase 3 KRYSTAL-12 study showed statistically significant and clinically meaningful improveme...

fda-expands-approval-for-bristol-myers-squibbs-breyanzi-making-car-t-cell-therapy-available-for-broadest-range-of-b-cell-malignancies
FDA Expands Approval For Bristol Myers Squ...
05/31/2024 18:14:15

FDA approves Bristol Myers Squibb's Breyanzi (lisocabtagene maraleucel) for relapsed or refractory mantle cell lymphoma, ma...

10-health-care-stocks-whale-activity-in-todays-session
10 Health Care Stocks Whale Activity In To...
05/31/2024 17:35:21

bristol-myers-squibbs-options-a-look-at-what-the-big-money-is-thinking
Bristol-Myers Squibb's Options: A Look at ...
05/30/2024 17:15:42

bristol-myers-squibb-announces-fda-approval-of-breyanzi-for-treatment-of-relapsed-or-refractory-mantle-cell-lymphoma
Bristol Myers Squibb Announces FDA Approva...
05/30/2024 15:52:16

are-boomers-crashing-the-economy-or-saving-it-why-investors-are-perplexed-and-what-you-can-do-to-prepare
Are Boomers Crashing The Economy Or Saving...
05/29/2024 14:51:04

Mass retirement of boomers could have major economic impact. Experts anticipate both risks and opportunities from the largest w...

european-commission-approves-bristol-myers-squibbs-opdivo-nivolumab-in-combination-with-cisplatin-and-gemcitabine-for-the-first-line-treatment-of-unresectable-or-metastatic-urothelial-carcinoma
European Commission Approves Bristol Myers...
05/29/2024 11:11:15

Approval based on results from CheckMate -901, the first Phase 3 trial in this patient population with an immunotherapy-chemo...

Core News & Articles
Prothena to Receive $80 Million from Brist...
05/28/2024 20:08:17

10-health-care-stocks-with-whale-alerts-in-todays-session
10 Health Care Stocks With Whale Alerts In...
05/28/2024 17:35:22

wall-streets-most-accurate-analysts-say-hold-these-3-health-care-stocks-with-over-4-dividend-yields
Wall Street's Most Accurate Analysts Say H...
05/28/2024 12:56:32

10-health-care-stocks-with-whale-alerts-in-todays-session
10 Health Care Stocks With Whale Alerts In...
05/24/2024 17:35:24

whats-going-on-with-mid-cap-cancer-focused-verastem-oncology-stock-on-friday
What's Going On With Mid-Cap Cancer-Focuse...
05/24/2024 12:45:21

Verastem Oncology reports promising initial results from the RAMP 205 trial with an 83% ORR for avutometinib and defactinib in ...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION